Effectiveness of implantable cardioverter defibrillator as primary prevention in hypertrophic cardiomyopathy: One year follow-up study

被引:0
|
作者
Fadaam, Hasan Ahmed [1 ]
Al-Musawi, Ali Abdul-Amir [1 ]
Al-Iqabby, Kasim Abbas Ismail [1 ]
机构
[1] Ibn Al Bitar Specialized Ctr Cardiac Surg, Baghdad, Iraq
来源
REVISTA LATINOAMERICANA DE HIPERTENSION | 2023年 / 18卷 / 01期
关键词
Hypertrophic Cardiomyopathy; Implantable cardioverter defibrillator; Sudden cardiac death; SUDDEN CARDIAC DEATH; VENTRICULAR-TACHYCARDIA; EFFICACY; RISK;
D O I
10.5281/zenodo.7778653
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Hereditary hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricular hypertrophy and varied clinical manifestations. The worst outcome of this disorder, ventricular fibrillation, is sudden cardiac death (SCD), hence the only effective treatment is an implanted cardioverter-defibrillator (ICD). Objective: ICD as a significant preventative technique for hypertrophic cardiomyopathy to avoid sudden cardiac death, study ICD shock risk factors and predictors, ICD suitable shock and their predictions. Method: In an observational, prospective cohort trial, 33 consecutive men and women got ICD treatment to prevent HCM. Patients aged 35-64 were examined at Ibn Al Bitar Specialist Center for Heart Surgery in 2017 for one-year follow-up. At ICD programming visits, all patients had transthoracic echocardiography and were compared to a previous echo exam. Results: 33 patients completed the investigation, with a mean age of 46.5 +/- 7.1, lowest age 35, highest age 64, and 1.2:1 male-to-female ratio. Non-sustained VT on Holter, family history of sudden cardiac death, repeated syncope episodes, and left ventricular wall thickness <30mm increased ICD implantation. 24.2% had two risks, 12.1% three, and 63.6% one. 36.4% positive ICD treatment, all ATP, and all shocks were tested. 27.3% had excellent ICD shock. Women experienced more ICD shocks than men regardless of age. SCD and syncope in the family elevated ICD shock rates. ICD shock risk was higher in women, repeated syncope, and sudden cardiac death families. ICD treatment helps younger patients, those with a positive family history of sudden cardiac death, non-sustained VT, and larger left ventricular outflow tract diameters. Conclusion: ICD shock is more frequent in women with a family history of SCD, syncope, and numerous risk factors. HCM patients with one risk factor may get an ICD as primary prevention. Several risk factors increase ICD shock risk. Inappropriate shock is linked to advanced age and decreased left ventricular outflow tract.
引用
收藏
页码:20 / 25
页数:6
相关论文
共 50 条
  • [1] Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy
    Nauffal, Victor
    Marstrand, Peter
    Han, Larry
    Parikh, Victoria N.
    Helms, Adam S.
    Ingles, Jodie
    Jacoby, Daniel
    Lakdawala, Neal K.
    Kapur, Sunil
    Michels, Michelle
    Owens, Anjali T.
    Ashley, Euan A.
    Pereira, Alexandre C.
    Rossano, Joseph W.
    Saberi, Sara
    Semsarian, Christopher
    Ware, James S.
    Wittekind, Samuel G.
    Day, Sharlene
    Olivotto, Iacopo
    Ho, Carolyn Y.
    EUROPEAN HEART JOURNAL, 2021, 42 (38) : 3932 - 3944
  • [2] Implantable Cardioverter-defibrillator Therapy for Hypertrophic Cardiomyopathy: Usefulness in Primary and Secondary Prevention
    Sarrias, Axel
    Galve, Enrique
    Sabate, Xavier
    Moya, Angel
    Anguera, Ignacio
    Nunez, Elaine
    Villuendas, Roger
    Alcalde, Oscar
    Garcia-Dorado, David
    REVISTA ESPANOLA DE CARDIOLOGIA, 2015, 68 (06): : 492 - 496
  • [3] Utilization and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Hypertrophic Cardiomyopathy
    Goldstein, Sarah A.
    Kennedy, Kevin F.
    Friedman, Daniel J.
    Al-Khatib, Sana M.
    Wang, Andrew
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (16):
  • [4] Low Agreement Among Guidelines for Primary Prevention Implantable Cardioverter-Defibrillator Recommendations in Hypertrophic Cardiomyopathy
    Scolari, Fernando Luis
    Garbin, Henrique Iahnke
    de Carvalho, Guilherme Dagostin
    Rodrigues, Fernanda Thomaz
    de Menezes, Rodrigo Araujo
    Correia, Edileide de Barros
    Bittencourt, Marcelo Imbroinise
    AMERICAN JOURNAL OF CARDIOLOGY, 2025, 236 : 86 - 91
  • [5] Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: A SIMPLE substudy
    Vamos, Mate
    Healey, Jeff S.
    Wang, Jia
    Connolly, Stuart J.
    Mabo, Philippe
    Van Erven, Lieselot
    Kautzner, Josef
    Glikson, Michael
    Neuzner, Jorg
    O'Hara, Gilles
    Vinolas, Xavier
    Gadler, Frederik
    Hohnloser, Stefan H.
    HEART RHYTHM, 2018, 15 (03) : 386 - 392
  • [6] Implantable Cardioverter-Defibrillator in PatientsWith Hypertrophic Cardiomyopathy: Efficacy and Complications of the Therapy in Long-Term Follow-up
    Syska, Pawel
    Przybylski, Andrzej
    Chojnowska, Lidia
    Lewandowski, Michal
    Sterlinski, Maciej
    Maciag, Aleksander
    Gepner, Katarzyna
    Pytkowski, Mariusz
    Kowalik, Ilona
    Maczynska-Mazuruk, Renata
    Ruzyllo, Witold
    Szwed, Hanna
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2010, 21 (08) : 883 - 889
  • [7] Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy
    Konstantinou, Dimitrios M.
    Efthimiadis, Georgios K.
    Vassilikos, Vassilios
    Paraskevaidis, Stylianos
    Pagourelias, Efstathios
    Maron, Barry J.
    Karvounis, Haralambos
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2016, 17 (06) : 433 - 439
  • [8] Follow-up of the patient with automatic implantable cardioverter defibrillator
    Cruz Cardentey, Marleny
    Prieto Guerra, Maidelis
    Gutierrez Lopez, Alain
    Mengana Betancourt, Ana
    Ramos Cordero, Michel Y.
    Tannis Wilson, Eko
    Tamargo Barbeito, Teddy O.
    CORSALUD, 2020, 12 (03): : 283 - 291
  • [9] Implantable Cardioverter-Defibrillator Therapy for Primary Prevention of Sudden Death After Alcohol Septal Ablation of Hypertrophic Cardiomyopathy
    Cuoco, Frank A.
    Spencer, William H., III
    Fernandes, Valerian L.
    Nielsen, Christopher D.
    Nagueh, Sherif
    Sturdivant, J. Lacy
    Leman, Robert B.
    Wharton, J. Marcus
    Gold, Michael R.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (21) : 1718 - 1723
  • [10] Defibrillation threshold testing during implantable cardioverter defibrillator implantation: 5-year follow-up
    Kim, Sung Soo
    Park, Hyung Wook
    Jeong, Hyung Ki
    Lee, Ki Hong
    Yoon, Nam Sik
    Cho, Jeong Gwan
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2021, 60 (03) : 485 - 491